Novo Nordisk A/S

Diabetes and Glycaemic Control

Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.

  • HbA1c reduction
  • Insulin icodec
  • Oral semaglutide
  • Diabetic retinopathy

Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.

Obesity and Weight Management

Focused research in obesity, overweight, and related metabolic risk states, including weight reduction and long-term weight maintenance in adults, adolescents, and children. Trials also cover obesity linked with type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, and post-menopausal obesity.

  • Cagrilintide
  • CagriSema
  • Semaglutide
  • Liraglutide

Research includes metabolic and appetite-related outcomes in adults and paediatric populations with excess body weight.

Cardiovascular, Renal, and Inflammatory Disease

Work spans heart failure, acute myocardial infarction, atherosclerotic cardiovascular disease, cardiometabolic disease, and chronic kidney disease, often in the setting of systemic inflammation. Studies also include transthyretin amyloid cardiomyopathy and cardiovascular risk reduction.

  • Ziltivekimab
  • ATTR cardiomyopathy
  • Major adverse cardiovascular events
  • Chronic kidney disease progression

Therapeutic interest includes inflammatory pathways in cardiovascular and renal disease, as well as outcomes linked to cardiac function and vascular injury.

Haematology and Blood Disorders

Research activity includes inherited bleeding disorders such as haemophilia A and haemophilia B, with and without factor VIII inhibitors. Studies also address sickle cell disease and thalassaemia.

  • Concizumab
  • Mim8
  • Bleeding prevention
  • Sickle cell disease

The portfolio reflects interest in prophylaxis, bleeding control, and the management of chronic haematologic complications across adult and paediatric populations.

Endocrine, Growth, and Rare Disease Areas

Additional research covers growth hormone deficiency, short stature, Turner syndrome, Noonan syndrome, and small for gestational age children. The sponsor also studies alzheimer’s disease, non-alcoholic steatohepatitis, alcohol-related liver disease, and hereditary haemochromatosis.

  • Somapacitan
  • Paediatric growth disorders
  • NASH
  • Mild cognitive impairment

These programmes include endocrine replacement, liver disease, and neurocognitive conditions, with interest in both common metabolic and less common inherited disorders.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on CDR132L for Heart Failure with Reduced Ejection Fraction and Left Ventricular Hypertrophy in Adults

    Recruiting

    2 1
    Investigated Diseases:
    Czechia Germany The Netherlands Poland Spain
  • Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Greece Italy The Netherlands Spain
  • Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Greece Italy Spain
  • Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Greece Hungary Italy +5
  • Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Greece Hungary Portugal Sweden
  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    Bulgaria Czechia Denmark France Germany Greece +4